River Global Investors LLP Purchases 93,340 Shares of MaxCyte, Inc. (NASDAQ:MXCT)

River Global Investors LLP boosted its position in shares of MaxCyte, Inc. (NASDAQ:MXCT) by 4.7% in the third quarter, Holdings Channel.com reports. The institutional investor owned 2,062,562 shares of the company’s stock after acquiring an additional 93,340 shares during the period. MaxCyte comprises approximately 1.7% of River Global Investors LLP’s investment portfolio, making the stock its 12th biggest holding. River Global Investors LLP’s holdings in MaxCyte were worth $8,034,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in MaxCyte by 1.2% during the first quarter. Vanguard Group Inc. now owns 5,347,112 shares of the company’s stock valued at $22,404,000 after buying an additional 65,004 shares during the last quarter. Swedbank AB bought a new stake in shares of MaxCyte in the 1st quarter valued at approximately $6,704,000. Chevy Chase Trust Holdings LLC lifted its stake in shares of MaxCyte by 2.0% in the 2nd quarter. Chevy Chase Trust Holdings LLC now owns 1,322,560 shares of the company’s stock valued at $5,184,000 after purchasing an additional 26,163 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of MaxCyte by 13.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,010,292 shares of the company’s stock valued at $3,961,000 after purchasing an additional 121,090 shares during the last quarter. Finally, Silvercrest Asset Management Group LLC lifted its stake in shares of MaxCyte by 4.5% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 699,089 shares of the company’s stock valued at $2,929,000 after purchasing an additional 30,209 shares during the last quarter. 68.81% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Stanley C. Erck sold 29,767 shares of the stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $3.97, for a total value of $118,174.99. Following the sale, the director now directly owns 269,118 shares in the company, valued at approximately $1,068,398.46. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, Director Stanley C. Erck sold 29,767 shares of the stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $3.97, for a total value of $118,174.99. Following the sale, the director now directly owns 269,118 shares in the company, valued at approximately $1,068,398.46. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Stanley C. Erck sold 21,607 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $3.71, for a total value of $80,161.97. Following the completion of the sale, the director now owns 269,118 shares in the company, valued at approximately $998,427.78. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 60,374 shares of company stock valued at $233,797 in the last ninety days. Insiders own 3.00% of the company’s stock.

MaxCyte Price Performance

Shares of NASDAQ:MXCT traded down $0.08 during trading on Friday, hitting $3.39. The company had a trading volume of 481,987 shares, compared to its average volume of 299,382. The stock has a market cap of $356.88 million, a price-to-earnings ratio of -9.96 and a beta of 1.40. MaxCyte, Inc. has a one year low of $3.15 and a one year high of $5.55. The company has a fifty day simple moving average of $3.83 and a two-hundred day simple moving average of $4.17.

MaxCyte Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.